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Burkholderia cenocepacia may cause serious infections in patients with cystic ﬁbrosis, and this
microorganism can be highly transmissible. Pulsed-ﬁeld gel electrophoresis is widely used
to  study the dynamics of strain spread in cystic ﬁbrosis patients. The aim of this work was  to
perform pulsed-ﬁeld gel electrophoresis-based molecular typing of B. cenocepacia isolates to
evaluate the epidemiology of this species at our hospital. A total of 28 isolates from 23 cystic
ﬁbrosis  patients were analyzed. Initially, we compared isolates obtained from the same
patient  at different periods of time. We  then compared the pulsed-ﬁeld gel electrophoresis
proﬁles  of 15 IIIA isolates, and in a third analysis, evaluated the genetic proﬁle of 8 IIIB
isolates  from different patients. The pulsed-ﬁeld gel electrophoresis proﬁles of isolates from
the same patient indicated that they are genetically indistinguishable. Analysis of isolates
from  different patients revealed the presence of multiple clonal groups. These results do not
indicate cross-transmission of a unique clone of B. cenocepacia among cystic ﬁbrosis patients,although  this has been observed in some patients. Our ﬁndings highlight the importance
of  adequate patient follow-up at cystic ﬁbrosis centers and adherence to management and
segregation  measures in cystic ﬁbrosis patients colonized with B. cenocepacia.
©  2013 Elsevier Editora Ltda. Open access under CC BY-NC-ND license.Burkholderia cepacia complex (BCC) is a group of closely related
Gram-negative bacteria that have emerged as opportunistic
pathogens among individuals with cystic ﬁbrosis (CF). BCC
was  described as 17 different species;1,2 however, studies have
reported  B. cenocepacia and B. multivorans as the predomi-
nant species in CF.3,4 B. cenocepacia (formerly known as BCC
genomovar III – phylogenetic subgroups IIIA, IIIB, IIIC and IIID)
has  been associated with rapid deterioration of lung function
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Open access under CC BY-NC-ND licensesecondary to necrotizing pneumonia and sepsis, resulting in
early death, among CF patients.5,6 This severe clinical con-
dition,  known as “cepacia syndrome,” was  ﬁrst recognized
in  the early 1980s, when a highly transmissible clone of B.de de Microbiologia e Biologia Molecular, Rua Ramiro Barcellos,
 51 3359 8310.
aris).
cenocepacia  IIIA (ET12) spread among CF patients in Canada,
England and Scotland.7 Inter-patient transmission can occur
during  hospitalization or through social contact between CF
patients  outside the hospital setting.8 Therefore, some CF
.
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Fig. 1 – Dendrogram of percent similarity among
pulsed-ﬁeld gel electrophoresis (PFGE) proﬁles of isolates
obtained  from the same patient at different points in timeb r a z j i n f e c t d i
enters have begun to adopt policies for segregation of “B.
enocepacia-positive” and “negative” patients to prevent B. ceno-
epacia  infection.4
Within this context, studies of the epidemiology of B. ceno-
epacia  play an essential role in guiding infection control
easures at CF centers. Consequently, the objective of this
tudy  was  to perform molecular typing by DNA macrorestric-
ion  followed by pulsed-ﬁeld gel electrophoresis (PFGE) of B.
enocepacia  isolates in order to evaluate the epidemiology of
his  pathogen in CF patients at Hospital de Clínicas de Porto
legre  (HCPA), a tertiary-level university hospital with more
han  800 beds in Porto Alegre, Brazil. The HCPA CF Reference
enter  provides care to nearly 250 CF patients. The hospi-
al  has a segregation program in place for BCC-colonized CF
atients:  colonized outpatients are seen on different days of
he  week than non-colonized CF patients, and colonized inpa-
ients  are admitted to isolation wards.
This study evaluated 28 B. cenocepacia isolates obtained
rom the sputum of 23 CF patients seen during the year 2008.
uring  the same period, Leite and coworkers studied a total
f  244 CF patients from HCPA and observed a prevalence rate
f  BCC of 10.6%. B. cenocepacia accounted for most BCC isolates
60%;  77.5% IIIA and 22.5% IIIB).9
Isolates were identiﬁed by phenotypic testing (charac-
eristic growth on BCSA medium, polymyxin B resistance,
yrrolidonyl arylamidase [PYR] negativity) and with the
iniAPI  semi-automated ID/AST system, using the 32GN card
BioMérieux).  B. cenocepacia identiﬁcation was  conﬁrmed by
ested  PCR using primers for recA as described by Drevínek
t  al. B. cenocepacia was  also used to identify phylogenetic sub-
roups  IIIA and IIIB.10 The majority of our isolates (67.8%) were
dentiﬁed  as genomovar IIIA (data not shown).
For PFGE analysis, DNA restriction was  carried out with
he  SpeI enzyme and electrophoresis was  performed in CHEF-
RII  equipment (Bio-Rad Laboratories). Run conditions were
s  described by Kutty et al.11 Proﬁles were analyzed in the
ioNumerics software environment (Applied Maths). The per-
entages  of similarity of the test isolates were identiﬁed on a
endrogram derived from the UPGMA algorithm and based on
he Dice coefﬁcient. A similarity coefﬁcient of 80% was used
o  deﬁne pulsed-ﬁeld type clusters.12
Three different analyses of isolates were performed on the
asis  of PFGE proﬁles. We ﬁrst compared isolate proﬁles within
he  same patient (using a subsample of 5 patients and 10 iso-
ates)  at different points in time (4–6 months apart). These
solates showed the same DNA macrorestriction proﬁle (100%
enetic  similarity – Fig. 1). On the basis of this ﬁnding, we
ecided  to include only one isolate from each patient for anal-
sis  of isolate similarity among different patients.
The second analysis included 15 IIIA isolates from different
atients. Nine different clonal groups (represented by letters A
o I) were  established (Fig. 2). Groups A, C, F, G, H and I included
nly  one isolate; group B included 3 isolates that displayed
00% genetic similarity; group D included 4 isolates, 3 of which
xhibited  100% similarity; and group E included 2 isolates also
isplaying  100% similarity. Notably, we found that the B. ceno-
epacia  IIIA isolates from CF patients in our sample exhibited
ittle  genetic similarity with the ET12 strain.
The third analysis included 8 IIIB isolates from different
atients and showed the presence of ﬁve distinct clonal groups(4–6  months apart).
(designated J to O) (Fig. 2). Groups L, N and O included only
one  isolate; group J included two isolates (710 and 768) that
displayed  100% genetic similarity; and group M included 3
isolates  (642, 656 and 706).
PFGE  analysis revealed the presence of clonal groups
formed by isolates with 100% genetic similarity and other
groups  with a similarity of >80%. We  observed many  differ-
ent  pulsotypes, most of which comprised only one isolate.
These  ﬁndings suggest the occurrence of multiple B. cenocepa-
cia  clonal groups among CF patients treated at HCPA, and,
therefore, indicate absence of cross-transmission of a unique
B.  cenocepacia clone among CF patients, although this phe-
nomenon  has been observed in some patients (e.g. with clonal
group  D). Indeed, there were instances of different patients
in  the sample being colonized by the same strain.Several
epidemiological studies have shown most cases of BCC infec-
tion  transmitted between CF patients involved B. cenocepacia
strains.13 The most dramatic clinical pictures were  associated
with  the ET12 strain.14 Apparently, ET12 is an endemic strain
isolated  predominantly at CF centers in North America and
Europe.  However, our ﬁndings show that, on PGFE analysis, the
DNA  macrorestriction proﬁle of ET12 strain isolates is quite
distinct  from that of B. cenocepacia IIIA isolates obtained from
CF  patients treated at HCPA.Our study also showed the per-
sistence  of particular genotype proﬁles in the same patients
over  time. In ﬁve patients, we observed the same B. cenocepa-
cia  clone in isolates collected 4–6 months apart. This suggests
that,  even during courses of antibiotic therapy, the original
strain  may  not be eradicated from some patients.15 Genotyp-
ing  studies have shown that chronic infection in CF patients is
typically associated with a single BCC strain. Transient coin-
fection  with two different BCC species or two strains of the
same  species may  occur, but this phenomenon is rare and
found  mainly in early infection.16
In summary, we  demonstrated the presence of multiple B.
cenocepacia  clonal groups among CF patients treated at Hos-
pital  de Clínicas de Porto Alegre. Our ﬁndings highlight the
importance  of adequate patient follow-up at CF centers and
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Fig. 2 – Dendrogram of percent similarity among pulsed-ﬁeld gel electrophoresis (PFGE) proﬁles of IIIA and IIIB isolates from
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1different patients. B. cenocepacia ET12 was  considered a high
adherence to management and segregation measures in CF
patients  colonized with B. cenocepacia.
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